Literature DB >> 18252121

Fecal viral concentration and diarrhea in norovirus gastroenteritis.

Nelson Lee1, Martin C W Chan, Bonnie Wong, K W Choi, Winnie Sin, Grace Lui, Paul K S Chan, Raymond W M Lai, C S Cockram, Joseph J Y Sung, Wai K Leung.   

Abstract

Fecal viral concentrations of 40 patients infected with norovirus genogroup GII.4 correlated with diarrhea duration and frequency of vomiting. Higher viral concentration and older age were independently associated with prolonged diarrhea (> or =4 days). These findings provide information on the pathogenesis and transmission of norovirus infections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18252121      PMCID: PMC2857278          DOI: 10.3201/eid1309.061535

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Norovirus is a major cause of viral gastroenteritis worldwide, accounting for at least 28% of all foodborne outbreaks (). However, its pathogenesis is poorly understood (). Although the disease is usually perceived as mild and self-limiting (symptoms generally subside within 2–3 days in otherwise healthy persons) (,), protracted diarrhea and serious complications may develop in elderly or immunocompromised patients (–). We have previously shown that patients infected with norovirus genogroup GII have at least 100-fold higher fecal viral concentrations than those infected with genogroup GI (), which may help explain the former’s global predominance (,). However, whether fecal viral concentration has any association with disease manifestation is unknown. In this study, we postulated that a higher viral concentration is associated with more severe symptoms. We studied potential associations in patients infected with norovirus GII.4, the predominant norovirus genotype circulating in Hong Kong during the study period (,).

The Study

During a 2-year period (November 2004–November 2006), 44 adult (>16 years of age) patients at 2 regional hospitals in Hong Kong Special Administrative Region with acute gastroenteritis were shown to be infected with norovirus genogroup GII.4. Clinical records were reviewed and baseline characteristics, clinical features, and output charts were studied. Cases were included for analysis if stool samples were collected <96 hours from symptom onset. Diarrhea was defined as having >3 loose stools per day. Duration of diarrhea was defined as the number of days (inclusive) between the first and final dates of symptoms (). Stool samples were collected from all patients when initially observed and processed immediately for RNA extraction. Diagnosis of norovirus infection and its quantitation were based on real-time reverse transcription–PCR assay of stool samples as described (). The lower detection limit of the assay was 2 × 104 copies of cDNA/g stool. Phylogenetic studies were also performed as described (). Associations between clinical parameters and fecal viral cDNA concentrations were determined. Univariate associations between fecal viral concentration (log10 copies cDNA/g fecal specimen), baseline characteristics, and clinical variables were examined by using the Mann-Whitney test or χ2 test as appropriate. Variables with a p value <0.1 in univariate analyses were entered into multivariate models as covariates. Stepwise backward logistic regression was performed to identify independent variables associated with prolonged diarrhea, defined as >4 days of diarrhea. This cut-off was based on the results of many observational studies (–) and was also above the median duration of diarrhea in this cohort. Spearman rank correlation coefficient (ρ) was used to assess correlations between viral cDNA concentration and other continuous variables. A p value <0.05 was considered statistically significant. All probabilities were 2-tailed. Statistical analysis was performed with SPSS software version 13.0 (SPSS Inc., Chicago, IL, USA). Stool samples from 40 patients were analyzed. Mean ± SD age of patients was 60.4 ± 24.3 years and 15 (37.5%) were males. Seventeen patients (42.5%) had pre-existing medical conditions, and 21 (52.5%) were hospitalized. Diarrhea was observed in 100%, whereas vomiting and fever were observed in 64.9% and 36.8%, respectively. Median duration of diarrhea was 3 days (range 2–6 days). Median fecal cDNA concentration was 8.93 log10 copies/g stool (interquartile range 8.22–10.24 log10 copies/g stool). Fecal viral cDNA concentration was examined in relation to baseline characteristics and clinical symptoms (Table). Higher viral concentrations were associated with older age (p = 0.064). Higher fecal viral concentration was significantly associated with prolonged diarrhea >4 days (2.11 log10 copies/g stool; p = 0.001, by Mann-Whitney test) than with limited diarrhea (Figure 1). Viral concentration was positively correlated with total duration of diarrhea (Spearman ρ 0.47, p = 0.004) and total frequency of vomiting (Spearman ρ 0.34, p = 0.043) during the course of illness (Appendix Figure). Fever developed more frequently in patients with prolonged diarrhea (64.3% vs. 21.7%; p = 0.010, by χ2 test). Mean total frequency of diarrhea and vomiting was 14.9 and 3.1, respectively, in inpatients with prolonged diarrhea and 11.8 and 1.2, respectively, in those with limited diarrhea. We did not observe an association between mean daily output and fecal viral concentrations in this cohort.
Table

Fecal viral concentrations of 40 patients infected with norovirus*

Comparison groups (%)Median fecal viral concentration, log10 copies cDNA/g stool (IQR)p value
Age, y
<65 (47.5)8.48 (7.79–10.11)0.064
>65 (52.5)8.97 (8.54–10.70)
Sex
Male (37.5)8.97 (7.79–10.72)0.706
Female (62.5)
8.88 (8.24–10.22)
Pre-existing medical conditions†
No (57.5)8.95 (7.86–10.26)0.520
Yes (42.5)8.91 (8.31–10.14)
Diarrhea duration‡
Limited (62.2)8.38 (7.89–9.45)0.001
Prolonged (37.8)
10.49 (8.84–10.94)
Vomiting
No (35.1)8.71 (7.71–9.91)0.215
Yes (64.9)9.10 (8.25–10.40)
Fever§
No (62.2)8.77 (8.15–10.17)0.380
Yes (36.8)9.13 (8.23–10.75)

*IQR, interquartile range.
†Includes diabetes mellitus, chronic cardiovascular/pulmonary/hepatic diseases, and underlying malignancies. No patient had conditions associated with profound immunosuppression in this cohort.
‡Limited (62.2%) is defined as a total duration of diarrhea of 1–3 d, including both hospitalized and nonhospitalized patients (followed up by the same hospital’s emergency departments as outpatients).Prolonged (37.8%) is defined as a total duration of diarrhea >4 d; all but 1 were hospitalized patients.
§Temperature >37.5°C on >1 occasion.

Figure 1

Box plot of median (black horizontal bars) and interquartile range (error bars) of fecal norovirus cDNA concentrations in patients with limited and prolonged diarrhea. Limited diarrhea is defined as a total duration of diarrhea of 1–3 days, and prolonged diarrhea is defined as a total duration of diarrhea ≥4 days.

*IQR, interquartile range.
†Includes diabetes mellitus, chronic cardiovascular/pulmonary/hepatic diseases, and underlying malignancies. No patient had conditions associated with profound immunosuppression in this cohort.
‡Limited (62.2%) is defined as a total duration of diarrhea of 1–3 d, including both hospitalized and nonhospitalized patients (followed up by the same hospital’s emergency departments as outpatients).Prolonged (37.8%) is defined as a total duration of diarrhea >4 d; all but 1 were hospitalized patients.
§Temperature >37.5°C on >1 occasion. Box plot of median (black horizontal bars) and interquartile range (error bars) of fecal norovirus cDNA concentrations in patients with limited and prolonged diarrhea. Limited diarrhea is defined as a total duration of diarrhea of 1–3 days, and prolonged diarrhea is defined as a total duration of diarrhea ≥4 days. To rule out possible confounding by variations in sample collection time, fecal viral cDNA concentration was also examined by sample collection day (Figure 2). In general, samples collected from patients with prolonged diarrhea had higher viral concentrations on all collection days. The mean day of sample collection was slightly later in patients with prolonged diarrhea than in those with limited symptoms (2.4 ± 1.3 days vs. 1.5 ± 1.1 days; p = 0.045, by t test).
Figure 2

Scatter plot showing fecal norovirus cDNA concentrations in patients with limited and prolonged diarrhea, according to sampling day. Limited diarrhea is defined as a total duration of diarrhea of 1–3 days, and prolonged diarrhea is defined as a total duration of diarrhea >4 days.

Scatter plot showing fecal norovirus cDNA concentrations in patients with limited and prolonged diarrhea, according to sampling day. Limited diarrhea is defined as a total duration of diarrhea of 1–3 days, and prolonged diarrhea is defined as a total duration of diarrhea >4 days. Prolonged diarrhea >4 days was associated with older age and pre-existing medical conditions by univariate analyses (p<0.05 for both variables, by χ2 test) and with fecal viral concentration. Stepwise backward logistic regression analysis showed that fecal viral concentration (odds ratio [OR] 9.56, 95% confidence interval [CI] 1.18–77.57 per log10 copies; p = 0.035) and age (OR 1.15, 95% CI 1.03–1.28) per year; p = 0.013) were 2 independent factors associated with prolonged diarrhea caused by norovirus genotype GII.4.

Conclusions

To our knowledge, this is the first clinical study to demonstrate that fecal viral concentration correlates with duration of illness in norovirus gastroenteritis. It has been reported that severe protracted diarrhea caused by norovirus infection can develop in hospitalized, elderly, and immunocompromised patients (,,). Such patients often shed virus for prolonged periods, which probably indicates active viral replication and slow viral clearance (,). In an animal model, norovirus was shown to infect and possibly replicate in enterocytes, resulting in disease (). Results of our study thus provide preliminary evidence that active viral replication determines clinical disease in norovirus gastroenteritis, as in most other viral infections (). These findings also suggest that more stringent infection control measures need to be implemented in patients with severe diarrhea because of high fecal viral concentrations (–,). This study was limited by a small sample size and fecal viral concentration, which was studied only at 1 time point for each patient. Further research on changes in fecal viral concentrations and their relationships with disease severity are warranted. Because no previous clinical studies describe temporal changes of norovirus concentration in relation to symptoms, we analyzed viral concentration data only in patients with acute diarrhea (days 0–4). Although our definition of prolonged diarrhea (>4 days, which was above the median in our cohort) seemed arbitrary, it is supported by the results of many observational studies, which show that in most patients (even elderly or hospitalized patients), acute symptoms subside within 2–3 days (–,). Inclusion of only norovirus GII.4 infections in the analysis removed the possible confounder of strain variation on viral concentration (). Whether similar correlations can be observed with other norovirus strains remains uncertain. Given that genogroup GII.4 is the predominant circulating strain in most countries with major outbreaks (), these results have implications with regard to pathogenesis and infection control of norovirus infections. In conclusion, these results provide preliminary evidence that a high fecal viral concentration is independently associated with prolonged norovirus gastroenteritis. Further studies are needed to confirm the role of enhanced viral replication on pathogenesis and transmission of this disease. In addition, the approach of quantifying norovirus by real-time PCR can be used for future evaluation of antiviral treatment () and to study factors associated with delayed viral clearance ().

Appendix Figure

A) Fecal viral concentrations (log10 copies cDNA/g stool) plotted against duration of diarrhea (d). B) Fecal viral concentrations (log10 copies cDNA/g stool) plotted versus total frequency of vomiting. Black horizontal bars show medians, and error bars show interquartile ranges.
  10 in total

Review 1.  The epidemiologic and clinical importance of norovirus infection.

Authors:  Robert L Atmar; Mary K Estes
Journal:  Gastroenterol Clin North Am       Date:  2006-06       Impact factor: 3.806

2.  Pathogenesis of a genogroup II human norovirus in gnotobiotic pigs.

Authors:  Sonia Cheetham; Menira Souza; Tea Meulia; Sheila Grimes; Myung Guk Han; Linda J Saif
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

3.  Long-term features of norovirus gastroenteritis in the elderly.

Authors:  J L Goller; A Dimitriadis; A Tan; H Kelly; J A Marshall
Journal:  J Hosp Infect       Date:  2004-12       Impact factor: 3.926

4.  Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial.

Authors:  J-F Rossignol; Y M El-Gohary
Journal:  Aliment Pharmacol Ther       Date:  2006-11-15       Impact factor: 8.171

5.  Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new norovirus variant.

Authors:  Ben Lopman; Harry Vennema; Evelyne Kohli; Pierre Pothier; Alicia Sanchez; Anabel Negredo; Javier Buesa; Eckart Schreier; Mark Reacher; David Brown; Jim Gray; Miren Iturriza; Chris Gallimore; Blenda Bottiger; Kjell-Olof Hedlund; Maria Torvén; Carl-Henrik von Bonsdorff; Leena Maunula; Mateja Poljsak-Prijatelj; Janet Zimsek; Gábor Reuter; György Szücs; Béla Melegh; Lennart Svennson; Yvonne van Duijnhoven; Marion Koopmans
Journal:  Lancet       Date:  2004-02-28       Impact factor: 79.321

6.  Reevaluation of epidemiological criteria for identifying outbreaks of acute gastroenteritis due to norovirus: United States, 1998-2000.

Authors:  Reina M Turcios; Marc-Alain Widdowson; Alana C Sulka; Paul S Mead; Roger I Glass
Journal:  Clin Infect Dis       Date:  2006-02-27       Impact factor: 9.079

7.  Clinical manifestation of norovirus gastroenteritis in health care settings.

Authors:  Ben A Lopman; Mark H Reacher; Ian B Vipond; Joyshri Sarangi; David W G Brown
Journal:  Clin Infect Dis       Date:  2004-07-09       Impact factor: 9.079

8.  Risk groups for clinical complications of norovirus infections: an outbreak investigation.

Authors:  F Mattner; D Sohr; A Heim; P Gastmeier; H Vennema; M Koopmans
Journal:  Clin Microbiol Infect       Date:  2006-01       Impact factor: 8.067

9.  Quantitation of group A rotavirus by real-time reverse-transcription-polymerase chain reaction: correlation with clinical severity in children in South India.

Authors:  Gagandeep Kang; Miren Iturriza-Gomara; Jeremy G Wheeler; Premila Crystal; Bindhu Monica; Sasirekha Ramani; Beryl Primrose; Prabhakar D Moses; Chris I Gallimore; David W Brown; Jim Gray
Journal:  J Med Virol       Date:  2004-05       Impact factor: 2.327

10.  Fecal viral load and norovirus-associated gastroenteritis.

Authors:  Martin C W Chan; Joseph J Y Sung; Rebecca K Y Lam; Paul K S Chan; Nelson L S Lee; Raymond W M Lai; Wai K Leung
Journal:  Emerg Infect Dis       Date:  2006-08       Impact factor: 6.883

  10 in total
  27 in total

1.  Diagnostic accuracy and analytical sensitivity of IDEIA Norovirus assay for routine screening of human norovirus.

Authors:  Verónica Costantini; LaDonna Grenz; Angela Fritzinger; David Lewis; Christianne Biggs; Antony Hale; Jan Vinjé
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

Review 2.  The epidemiology of published norovirus outbreaks: a review of risk factors associated with attack rate and genogroup.

Authors:  J E Matthews; B W Dickey; R D Miller; J R Felzer; B P Dawson; A S Lee; J J Rocks; J Kiel; J S Montes; C L Moe; J N S Eisenberg; J S Leon
Journal:  Epidemiol Infect       Date:  2012-03-26       Impact factor: 2.451

3.  Concentration of norovirus during wastewater treatment and its impact on oyster contamination.

Authors:  John Flannery; Sinéad Keaveney; Paulina Rajko-Nenow; Vincent O'Flaherty; William Doré
Journal:  Appl Environ Microbiol       Date:  2012-02-24       Impact factor: 4.792

4.  Presence of enteric viruses in source waters for drinking water production in The Netherlands.

Authors:  W J Lodder; H H J L van den Berg; S A Rutjes; A M de Roda Husman
Journal:  Appl Environ Microbiol       Date:  2010-07-09       Impact factor: 4.792

Review 5.  A review of known and hypothetical transmission routes for noroviruses.

Authors:  Elisabeth Mathijs; Ambroos Stals; Leen Baert; Nadine Botteldoorn; Sarah Denayer; Axel Mauroy; Alexandra Scipioni; Georges Daube; Katelijne Dierick; Lieve Herman; Els Van Coillie; Mieke Uyttendaele; Etienne Thiry
Journal:  Food Environ Virol       Date:  2012-11-03       Impact factor: 2.778

6.  DNA microarray for detection of gastrointestinal viruses.

Authors:  Miguel A Martínez; María de Los Dolores Soto-Del Río; Rosa María Gutiérrez; Charles Y Chiu; Alexander L Greninger; Juan Francisco Contreras; Susana López; Carlos F Arias; Pavel Isa
Journal:  J Clin Microbiol       Date:  2014-10-29       Impact factor: 5.948

Review 7.  Developments in understanding acquired immunity and innate susceptibility to norovirus and rotavirus gastroenteritis in children.

Authors:  Daniel C Payne; Umesh D Parashar; Benjamin A Lopman
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

8.  Phylodynamic reconstruction reveals norovirus GII.4 epidemic expansions and their molecular determinants.

Authors:  J Joukje Siebenga; Philippe Lemey; Sergei L Kosakovsky Pond; Andrew Rambaut; Harry Vennema; Marion Koopmans
Journal:  PLoS Pathog       Date:  2010-05-06       Impact factor: 6.823

9.  Preliminary evaluation of BioFire FilmArray® Gastrointestinal Panel for the detection of noroviruses and other enteric viruses from wastewater and shellfish.

Authors:  Pradip Gyawali; Dawn Croucher; Joanne Hewitt
Journal:  Environ Sci Pollut Res Int       Date:  2018-08-07       Impact factor: 4.223

10.  Norovirus and medically attended gastroenteritis in U.S. children.

Authors:  Daniel C Payne; Jan Vinjé; Peter G Szilagyi; Kathryn M Edwards; Mary Allen Staat; Geoffrey A Weinberg; Caroline B Hall; James Chappell; David I Bernstein; Aaron T Curns; Mary Wikswo; S Hannah Shirley; Aron J Hall; Benjamin Lopman; Umesh D Parashar
Journal:  N Engl J Med       Date:  2013-03-21       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.